An evaluation of bleeding risks Among Nonvalvular Atrial Fibrillation (NVAF) Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin

Trial Profile

An evaluation of bleeding risks Among Nonvalvular Atrial Fibrillation (NVAF) Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Nov 2016 New trial record
    • 16 Nov 2016 Results (n=17,127) presented at the 89th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top